NKG2 proteins: Checkpoint targets for immunotherapy

NKG2A and NKG2D are part of the NKG2 (CD159) family of proteins. These proteins are primarily expressed on cytotoxic immune cells, offering appealing new targets for ongoing immune checkpoint modulator development efforts.

As an inhibitory receptor, NKG2A forms a heterodimer with CD94 (KLRD1). In non-target cells, this CD94/NKG2A complex will interact with the non-classical MHC class I molecule HLA-E, inhibiting NK cell and T cell activation via the tyrosine phosphatases SHP-1 or SHP-2 signaling cascades.

Much like other immune checkpoints (for example, PD-1/PD-L1), CD94/NKG2A-HLA-E is leveraged by cancer cells seeking to evade the immune system.

As an activating receptor, NKG2D is a vital anti-tumor signaling axis. It is activated in humans by its ligands, including MICA, MICB, and ULBPs (ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6). This receptor is activated by the H60 (a–c), RAE(α–ε) and MULT1 families in mice.

In mice, NKG2D employs the adaptor molecules DAP10 and DAP12 to help relay its signal transduction. In humans, however, NKG2D has been found to associate exclusively with DAP10. It has a key role to play in fighting against viral infections, and can also regulate cytokine production; for example, IL-10, IL-9, IL-13.

NKG2D/NKG2D ligands

Sino Biological has successfully developed a number of high-activity NKG2D and NKG2D ligands proteins from a number species. These proteins are designed to help researchers study NKG2D/NKG2D ligand biology.

Binding activity validated by ELISA assay

Ligands bind with NKG2D (Cat#: 10575-H07B)

Human ULBP1 (Cat#: 10679-H03H).

Human ULBP1 (Cat#: 10679-H03H). Image Credit: Sino Biological Inc.

Human ULBP6 (Cat#: 15759-H02H).

Human ULBP6 (Cat#: 15759-H02H). Image Credit: Sino Biological Inc.

NKG2D binds with MICA (Cat#: 12302-H08H)

Human NKG2D (Cat#: 10575-H01S).

Human NKG2D (Cat#: 10575-H01S). Image Credit: Sino Biological Inc.
 

NKG2A and NKG2A ligand proteins from a number of species have also been developed, along with a comprehensive panel of antibodies designed to target MICA, MICB, NKG2A, NKG2D, NKG2E, ULBP1 and ULBP2.

Table 1. Source: Sino Biological Inc.

. . . .
Human NKG2A (13905-H07H1)
Tag: His
Expressed Host:
HEK293 Cells
Purity:
>90% (SDS-PAGE)
Human NKG2A (13905-H07H1-B)
Tag: His, Biotinylated
Expressed Host:
HEK293 Cells
Purity:
85% (SDS-PAGE)
Mouse NKG2A (50834-M07H)
Tag: His
Expressed Host:
HEK293 Cells
Purity:
>95% (SDS-PAGE)
Human CD94 (12649-H01H)
Tag: hFc
Expressed Host:
HEK293 Cells
Purity:
>95% (SDS-PAGE)

 

These antibodies can be used in ELISA, FCM, WB, IHC, IF and more. A human MICB ELISA kit and ELISA pair set can also be provided on request.

Anti-NKG2A antibodies

Table 2. Source: Sino Biological Inc.

. .
Human NKG2A (13905-T16)
Type: Rabbit PAb
Ig Type: Rabbit IgG
Application: ELISA
 
Mouse NKG2A (50834-RP01)
Type: Rabbit PAb
Ig Type: Rabbit IgG
Application: ELISA
 

 

Anti-NKG2D antibodies

Table 3. Source: Sino Biological Inc.

. .
Human NKG2D (10575-MM02)
Type: Mouse MAb
Ig Type: Mouse IgG3
Application: ELISA
 
Human NKG2D (10575-T16)
Type: Rabbit PAb
Ig Type: Rabbit IgG
Application: ELISA
 

 

About Sino Biological Inc.

Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.

Sino Biological's core business

Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and produced. In addition, we offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. Our product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks for us to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Aug 11, 2021 at 6:56 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2021, August 11). NKG2 proteins: Checkpoint targets for immunotherapy. News-Medical. Retrieved on November 28, 2021 from https://www.news-medical.net/whitepaper/20210809/NKG2-proteins-Checkpoint-targets-for-immunotherapy.aspx.

  • MLA

    Sino Biological Inc.. "NKG2 proteins: Checkpoint targets for immunotherapy". News-Medical. 28 November 2021. <https://www.news-medical.net/whitepaper/20210809/NKG2-proteins-Checkpoint-targets-for-immunotherapy.aspx>.

  • Chicago

    Sino Biological Inc.. "NKG2 proteins: Checkpoint targets for immunotherapy". News-Medical. https://www.news-medical.net/whitepaper/20210809/NKG2-proteins-Checkpoint-targets-for-immunotherapy.aspx. (accessed November 28, 2021).

  • Harvard

    Sino Biological Inc.. 2021. NKG2 proteins: Checkpoint targets for immunotherapy. News-Medical, viewed 28 November 2021, https://www.news-medical.net/whitepaper/20210809/NKG2-proteins-Checkpoint-targets-for-immunotherapy.aspx.

Other White Papers by this Supplier